A Phase 2, Multicenter, Open-Label Study of Lurbinectedin Efficacy and Safety in Participants with Advanced or Metastatic Solid Tumors
This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in participants with advanced (metastatic and/or unresectable) solid tumors.
* To evaluate the antitumor activity of lurbinectedin in the selected advanced solid tumors
* To evaluate the overall safety profile of lurbinectedin in the selected advanced solid tumors
* To assess other antitumor efficacy parameters of lurbinectedin in the selected advanced solid tumors.
* To assess OS in participants treated with lurbinectedin in the selected advanced solid tumors.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub